Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
Elena Fountzilas(St. Luke's Hospital), Dimitrios Bafaloukos(Metropolitan Hospital), Anastasios Boutis(Theageneio General Hospital), Eleni Res(Hospital Agioi Anargyroi), Georgia-Angeliki Koliou(Hellenic Cooperative Oncology Group), Sofia Lampaki(Aristotle University of Thessaloniki), Iliada Bompolaki(Chania General Hospital ”St. George”), Dimitrios Daoussis(University of Patras), Athanasios Laloysis(Hygeia Hospital), George Fountzilas(Hellenic Cooperative Oncology Group), Marinos Tsiatas(Athens Medical Center), Giannis Mountzios(Henry Dunant Hospital), Dionisiοs Spyratos(Aristotle University of Thessaloniki), Α. Kotsakis(University of Thessaly), Ηλίας Κοττέας(National and Kapodistrian University of Athens), Emmanouil Saloustros(University of Thessaly), Amanda Psyrri(National and Kapodistrian University of Athens), Athina Christopoulou(General University Hospital of Patras), Miltiadis Chrysanthidis(Metropolitan Hospital), George Papaxoinis(St Savas Hospital), Vassilis Georgoulias(Hellenic Oncology Research Group), Anastasios Vagionas(Technological Educational Institute of Eastern Macedonia and Thrace), Henry Hiep Vo(The University of Texas MD Anderson Cancer Center), Ioannis Binas(Metropolitan Hospital), Anna Koumarianou(University General Hospital Attikon), Nikolaos Kentepozidis(Hellenic Airforce General Hospital), Helen Gogas(National and Kapodistrian University of Athens), Konstantinos N. Syrigos(National and Kapodistrian University of Athens), Sofia Levva(Interbalkan Medical Center), Helena Linardou(Metropolitan Hospital), Anna Andreadou(Theageneio General Hospital), Adamantia Nikolaidi(Mitera Hospital)
Cited by 39
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747